P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Jan 2019
At a glance
- Drugs MVA-p53 (Primary) ; Pembrolizumab (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 28 Dec 2018 Planned initiation date changed from 1 Dec 2018 to 1 Mar 2019.
- 08 Oct 2018 Planned initiation date changed from 1 Sep 2018 to 1 Dec 2018.
- 31 Aug 2018 Biomarkers information updated